Charles Schwab Investment Management Inc. increased its holdings in Disc Medicine, Inc. (NASDAQ:IRON – Free Report) by 2.8% ...

Disc Medicine (NASDAQ:IRON – Get Free Report) is expected to be posting its quarterly earnings results before the market ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Q4 2024 Earnings Call Transcript March 20, 2025 Autolus Therapeutics plc beats earnings expectations. Reported EPS is $-0.09, ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Spun off from Labcorp in 2023 to focus exclusively on clinical research services, Fortrea (NASDAQ:FTRE) is a contract research organization that helps pharmaceutical, biotech, and medical device ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Johnson & Johnson has announced a $55 billion investment in the U.S. over the next four years. This move will boost American ...

Novanta’s stock price has taken a beating over the past six months, shedding 21.9% of its value and falling to a new 52-week ...

Fintel reports that on March 21, 2025, Piper Sandler downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from ...

Amneal Pharmaceuticals (AMRX) is experiencing significant financial growth by focusing on making generic drugs more affordable and accessible—a ...